Nektar Therapeutics held its Annual Meeting of Stockholders on June 5, 2024, where various proposals were voted on and approved, including the election of directors, amendment to the Performance Incentive Plan, selection of Ernst & Young LLP as the independent registered public accounting firm, and approval of the non-binding advisory resolution regarding executive compensation.